Obituary: Barry Sherman

Apotex has paid its respects to the company’s founder and chairman, Barry Sherman, 75, and his wife Honey, 70, after they were found dead at their home in Toronto, Canada, on 15 December. The Canadian firm said it was with “profound sadness that we announce the unexpected passing” of Sherman, who founded privately-held Apotex in 1974. “From its humble two-employee, 5,000 square-feet beginning in Toronto, the company Dr Sherman founded grew into a global pharmaceutical organisation that today employs more than 11,000 people in research, development, manufacturing and distribution in facilities around the world,” Apotex commented.

Apotex has paid its respects to the company’s founder and chairman, Barry Sherman, 75, and his wife Honey, 70, after they were found dead at their home in Toronto, Canada, on 15 December. The Canadian firm said it was with “profound sadness that we announce the unexpected passing” of Sherman, who founded privately-held Apotex in 1974. “From its humble two-employee, 5,000 square-feet beginning in Toronto, the company Dr Sherman founded grew into a global pharmaceutical organisation that today employs more than 11,000 people in research, development, manufacturing and distribution in facilities around the world,” Apotex commented.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Generics Bulletin

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By 

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By 

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By 

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.